|
Reductions in cancer screening: The consequence of changes in routine care during the COVID-19 pandemic. |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Employment - BluePath Solutions |
Leadership - BluePath Solutions |
Stock and Other Ownership Interests - Juno Therapeutics |
Consulting or Advisory Role - BluePath Solutions (Inst) |
Research Funding - BluePath Solutions (Inst) |
Travel, Accommodations, Expenses - BluePath Solutions (Inst) |
|
|
Consulting or Advisory Role - GRAIL |
|
|
|
Consulting or Advisory Role - Allergan (Inst); Amgen (Inst); Autolus (Inst); Bristol-Myers Squibb/Celgene (Inst); GRAIL (Inst); Iovance Biotherapeutics (Inst); Omeros (Inst) |
Research Funding - Allergan (Inst); Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); GRAIL (Inst); Omeros (Inst); OPKO Biologics (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Celgene; GRAIL |
Stock and Other Ownership Interests - Amgen; Baxter; Bayer; Celgene; Gilead Sciences; GRAIL; Jazz Pharmaceuticals; Takeda |